BridgeBio Oncology (BBOT) director Kelleher files Form 3 showing no share ownership

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. director Raymond J. Kelleher filed an initial ownership report on Form 3. The filing states that as of the event date of 08/11/2025, he has no beneficial ownership of the company’s securities, and no derivative securities are reported.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kelleher Raymond J.

(Last) (First) (Middle)

C/O HELIX ACQUISITION CORP. II

200 CLARENDON STREET, 52ND FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Raymond J. Kelleher	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Raymond J. Kelleher’s Form 3 for BridgeBio Oncology Therapeutics, Inc. (BBOT) show?

The Form 3 shows that director Raymond J. Kelleher reported no beneficial ownership of BridgeBio Oncology Therapeutics, Inc. securities as of 08/11/2025. No non-derivative or derivative securities are listed in the filing’s ownership tables.

What is the significance of filing a Form 3 for BridgeBio Oncology Therapeutics, Inc. (BBOT)?

Form 3 is the initial statement of beneficial ownership required when someone becomes an insider, such as a director. It establishes a public baseline of their holdings, which in this filing is reported as none for BBOT securities.

Does director Raymond J. Kelleher own any BridgeBio Oncology Therapeutics, Inc. (BBOT) shares or options?

According to the Form 3, no securities are beneficially owned by Raymond J. Kelleher. Both the non-derivative and derivative security tables are effectively empty, and the explanation of responses confirms that no securities are beneficially owned.

What role does Raymond J. Kelleher have at BridgeBio Oncology Therapeutics, Inc. (BBOT)?

The Form 3 identifies Raymond J. Kelleher as a director of BridgeBio Oncology Therapeutics, Inc. He is not listed as an officer or 10% owner in the filing, and no other relationship boxes are checked.

What is the event date reported on Raymond J. Kelleher’s Form 3 for BBOT?

The Form 3 lists 08/11/2025 as the date of the event requiring the statement. This date typically corresponds to when Kelleher became an insider, such as joining the board as a director of BridgeBio Oncology Therapeutics, Inc.

Are any indirect holdings reported for Raymond J. Kelleher in BridgeBio Oncology Therapeutics, Inc. (BBOT)?

No indirect holdings are reported. The ownership tables show no entries, and the explanation section clearly states that no securities are beneficially owned, covering both direct and indirect beneficial ownership for BBOT securities.